Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHILLION PHARMACEUTICALS INCACHN · Entity 12234 | Director · Chief Executive Officer | February 09, 2018 | February 13, 2018 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Director | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHILLION PHARMACEUTICALS INC
Report date February 09, 2018 · Filed February 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2028-02-09 | Direct | 640,000 |
Reported balance
After 2018-02-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-09 · Grant · Acquired 640,000 · Balance 640,000 F1: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.
Spero Therapeutics, Inc.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 101,454 |
Reported balance
After 2026-06-23 transaction · row 1
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 10,000 · Balance 101,454 F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.15 · Expires 2036-06-23 | Direct | 20,000 |
Reported balance
After 2026-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-23 · Grant · Acquired 20,000 · Balance 20,000 F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 25, 2026 23:26 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001193125-26-283245 · ownership.xml · derivative · entry 2 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-06-23 F2 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 23:26 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-283245 · ownership.xml · nonDerivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,454 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:30 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087020 · ownership.xml · nonDerivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,454 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 12, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:29 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066659 · ownership.xml · nonDerivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,454 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on May 29, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 21:34 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-052710 · ownership.xml · nonDerivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,454 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on October 5, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 21:44 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-031504 · doc4.xml · nonDerivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,454 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on September 15, 2023, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 20:56 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0000899243-21-033469 · doc4.xml · derivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-08-17 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:27 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 2,629 | $13.31 Strike: $17.93 | $34,991.99 |
DisclosureSEC source: 0000899243-21-000690 · doc4.xml · derivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,629 Underlying: Common Stock · 2,629 shares Expires 2031-01-04 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $35,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| October 27, 2020 Filed Oct 27, 2020 21:32 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $13.52 | $0.00 |
DisclosureSEC source: 0000899243-20-029329 · doc4.xml · derivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-10-27 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on October 27, 2021 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 00:03 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 5,408 | $6.47 Strike: $9.87 | $34,989.76 |
DisclosureSEC source: 0000899243-20-000625 · doc4.xml · derivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,408 Underlying: Common Stock · 5,408 shares Expires 2030-01-02 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $35,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| June 05, 2019 Filed Jun 5, 2019 22:47 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $10.67 | $0.00 |
DisclosureSEC source: 0000899243-19-015665 · doc4.xml · derivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2020 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 00:00 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0000899243-18-015326 · doc4.xml · derivative · entry 1 Deshpande Milind · CIK 0001378588 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 17:27 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantEmployee Stock Option · Derivative | 640,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-009678 · doc4.xml · derivative · entry 1 Deshpande Milind · CIK 0001378588 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 Underlying: Common Stock · 640,000 shares Expires 2028-02-09 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 17:21 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantEmployee Stock Option · Derivative | 458,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001209191-17-004601 · doc4.xml · derivative · entry 1 Deshpande Milind · CIK 0001378588 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,000 Underlying: Common Stock · 458,000 shares Expires 2027-01-01 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period following the first anniversary of the grant date until the fourth anniversary of the grant date. Read SEC document |
| December 02, 2016 Filed Dec 5, 2016 17:16 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | PurchaseCommon Stock | 2,500 | $4.06 | $10,150.00 |
DisclosureSEC source: 0001209191-16-153418 · doc4.xml · nonDerivative · entry 1 Deshpande Milind · CIK 0001378588 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.